Entero Therapeutics, Inc.
ENTO
$0.3541
-$0.0241-6.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.87% | -47.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.41% | -44.76% | |||
| Operating Income | 36.41% | 44.76% | |||
| Income Before Tax | 37.00% | 44.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -522.52% | 75.34% | |||
| Earnings from Discontinued Operations | 35.90% | 38.90% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -374.17% | 70.70% | |||
| EBIT | 36.41% | 44.76% | |||
| EBITDA | 34.55% | 44.22% | |||
| EPS Basic | -470.42% | 84.81% | |||
| Normalized Basic EPS | 160.80% | 72.16% | |||
| EPS Diluted | -470.42% | 84.81% | |||
| Normalized Diluted EPS | 160.80% | 72.16% | |||
| Average Basic Shares Outstanding | -24.54% | 98.41% | |||
| Average Diluted Shares Outstanding | -24.54% | 98.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||